Optimizing Frontline Therapy for DLBCL in Older Adults: A GLOfitamab-based, Response-adapted, Window-stYle Study (GLORY)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Glofitamab (Primary) ; Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms GLORY
- 28 Jan 2025 Status changed from not yet recruiting to recruiting.
- 15 Jan 2025 New trial record